[go: up one dir, main page]

DK3551166T3 - Topisk phenytoin til anvendelse i behandling af periferisk neuropatisk smerte - Google Patents

Topisk phenytoin til anvendelse i behandling af periferisk neuropatisk smerte Download PDF

Info

Publication number
DK3551166T3
DK3551166T3 DK17817927.1T DK17817927T DK3551166T3 DK 3551166 T3 DK3551166 T3 DK 3551166T3 DK 17817927 T DK17817927 T DK 17817927T DK 3551166 T3 DK3551166 T3 DK 3551166T3
Authority
DK
Denmark
Prior art keywords
treatment
neuropathic pain
peripheral neuropathic
phenytoin
topical
Prior art date
Application number
DK17817927.1T
Other languages
English (en)
Inventor
Hesselink Jan Marius Keppel
David Jos Kopsky
Original Assignee
Topical Innovations B V
Hesselink Jan Marius Keppel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Topical Innovations B V, Hesselink Jan Marius Keppel filed Critical Topical Innovations B V
Application granted granted Critical
Publication of DK3551166T3 publication Critical patent/DK3551166T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41661,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK17817927.1T 2016-12-06 2017-12-06 Topisk phenytoin til anvendelse i behandling af periferisk neuropatisk smerte DK3551166T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL2017931 2016-12-06
PCT/NL2017/050814 WO2018106107A1 (en) 2016-12-06 2017-12-06 Topical phenytoin for use in the treatment of peripheral neuropathic pain

Publications (1)

Publication Number Publication Date
DK3551166T3 true DK3551166T3 (da) 2024-10-21

Family

ID=57796933

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17817927.1T DK3551166T3 (da) 2016-12-06 2017-12-06 Topisk phenytoin til anvendelse i behandling af periferisk neuropatisk smerte

Country Status (21)

Country Link
US (1) US11285099B2 (da)
EP (1) EP3551166B1 (da)
JP (1) JP7264813B2 (da)
CN (1) CN110248644A (da)
AU (1) AU2017371467B2 (da)
BR (1) BR112019011743A2 (da)
CA (1) CA3046055A1 (da)
CL (1) CL2019001550A1 (da)
DK (1) DK3551166T3 (da)
DO (1) DOP2019000156A (da)
EA (1) EA201991341A1 (da)
ES (1) ES2991885T3 (da)
FI (1) FI3551166T3 (da)
IL (1) IL267114B2 (da)
MA (1) MA51978A (da)
MX (1) MX2019006640A (da)
PH (1) PH12019550093A1 (da)
PT (1) PT3551166T (da)
UA (1) UA125040C2 (da)
WO (1) WO2018106107A1 (da)
ZA (1) ZA201906473B (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12005034B2 (en) 2017-04-25 2024-06-11 Algotherapeutix Topical pharmaceutical composition comprising at least amitriptyline, for the treatment of peripheral neuropathic pain
FR3095589B1 (fr) * 2019-05-02 2021-05-07 Air Liquide Mélange gazeux inhalable pour traiter les douleurs chroniques chez des patients recevant des médicaments de plusieurs classes thérapeutiques
EP4025183B1 (en) 2019-09-02 2025-06-18 Syddansk Universitet P-gp inducers as protectors against chemotherapy-induced side effects, such as peripheral neuropathy (cipn) and hair loss
FR3108841B1 (fr) 2020-04-06 2023-11-03 Algotherapeutix Composition pharmaceutique topique sous forme de gel aqueux comprenant au moins de l’amitriptyline
CN114681340A (zh) * 2022-04-13 2022-07-01 肌赋萃生物科技(上海)有限公司 一种含有脂质包裹稳定技术的脂质屏障修复护肤品及其制备方法
CN118647404A (zh) * 2022-12-09 2024-09-13 荣昌生物制药(烟台)股份有限公司 Cyp3a4/5诱导剂在治疗或缓解周围神经病变中的应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571521A (en) 1984-01-16 1996-11-05 Lasker; Sigmund E. Composition containing silver ammonium phenytoin complex and a phenytoin and use of said composition
JPH0772190B2 (ja) * 1985-02-26 1995-08-02 エーザイ株式会社 ヒダントイン誘導体
JP3031973B2 (ja) 1990-08-16 2000-04-10 富士レビオ株式会社 フェニトイン誘導体
US6113921A (en) * 1993-03-23 2000-09-05 Pharmos Corp. Topical and transdermal delivery system utilizing submicron oil spheres
CN1046199C (zh) * 1994-12-13 1999-11-10 凌吉安 复方消炎止痛霜剂
EP0942752B1 (en) 1996-08-23 2005-04-20 Algos Pharmaceutical Corporation Anticonvulsant containing composition for treating neuropathic pain
AU5824800A (en) * 1999-06-23 2001-01-31 Warner-Lambert Company Use of fosphenytoin for the treatment of acute neuropathic pain
US20040191276A1 (en) 1999-11-30 2004-09-30 Cutispharma, Inc. Compositions and kits for compounding pharmaceuticals
RU2262922C2 (ru) 2001-05-15 2005-10-27 Уорнер-Ламберт Компани Ллс Способ прессования для получения лекарственной формы фенитоина натрия
US7687080B2 (en) 2002-11-25 2010-03-30 Taraxos Inc. Treatment of neuropathy
NZ553024A (en) 2004-08-03 2009-11-27 Royal College Of Surgeons Ie Phenytoin formulations, and uses thereof in wound healing
US20060034910A1 (en) * 2004-08-09 2006-02-16 Sanjay Patel Pharmaceutical composition for extended release of phenytoin sodium
CN101069692B (zh) * 2006-05-08 2011-04-20 范敏华 含积雪草总甙的药物制剂及其制备方法
US20100029618A1 (en) 2006-12-22 2010-02-04 Gil Daniel W Alpha-2 receptor pan agonist and anticonvulsant compositions for treating chronic pain
EP2286828B1 (en) * 2008-04-14 2016-05-18 National University Corporation Nagoya University Improving agent for neuropathic pain
US8592424B2 (en) 2008-06-30 2013-11-26 Afgin Pharma Llc Topical regional neuro-affective therapy
WO2010036937A1 (en) 2008-09-27 2010-04-01 Taraxos Inc. Topical formulations for treatment of neuropathy
KR101271219B1 (ko) * 2011-01-27 2013-06-07 광주과학기술원 신규한 하이단토인 유도체 및 이의 용도
WO2012176668A1 (ja) 2011-06-20 2012-12-27 久光製薬株式会社 リドカイン含有パップ剤
US20130184351A1 (en) 2011-12-21 2013-07-18 Jar Laboratories Lidocaine patch and methods of use thereof
US9345689B2 (en) * 2012-05-18 2016-05-24 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N, N-dimethyl-4-phenyl-4,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and an anticonvulsant
WO2015089050A1 (en) * 2013-12-09 2015-06-18 Malshe Research And Development, Llc Compositions and methods for the treatment of wounds
CN106075556A (zh) * 2016-06-02 2016-11-09 四川奎星医用高分子制品有限责任公司 含有促进伤口愈合药物的医用复合壳聚糖凝胶

Also Published As

Publication number Publication date
EP3551166A1 (en) 2019-10-16
US20200276106A1 (en) 2020-09-03
UA125040C2 (uk) 2021-12-29
JP2020500915A (ja) 2020-01-16
EP3551166B1 (en) 2024-08-21
CA3046055A1 (en) 2018-06-14
ES2991885T3 (es) 2024-12-05
JP7264813B2 (ja) 2023-04-25
WO2018106107A1 (en) 2018-06-14
CN110248644A (zh) 2019-09-17
US11285099B2 (en) 2022-03-29
PT3551166T (pt) 2024-10-28
AU2017371467A1 (en) 2019-07-25
BR112019011743A2 (pt) 2019-10-22
FI3551166T3 (fi) 2024-10-04
IL267114B2 (en) 2024-08-01
EA201991341A1 (ru) 2019-12-30
IL267114B1 (en) 2024-04-01
AU2017371467B2 (en) 2023-06-01
MA51978A (fr) 2021-01-20
IL267114A (en) 2019-08-29
ZA201906473B (en) 2020-07-29
MX2019006640A (es) 2019-08-01
PH12019550093A1 (en) 2020-02-10
CL2019001550A1 (es) 2020-02-28
DOP2019000156A (es) 2020-07-15

Similar Documents

Publication Publication Date Title
DK3882250T3 (da) Tetrahydropyranyl-amino-pyrrolopyrimidinon til anvendelse i behandling af btk-medierede forstyrrelser
DK3334422T3 (da) Anvendelse af cannabidiolsyre i behandling af epilepsi
DK3490582T3 (da) Sammensætninger til anvendelse i behandling af myelofibrose
PL3157512T3 (pl) Zastosowanie kannabidioli w leczeniu padaczki
DK3504187T3 (da) Anvendelse af pridopidin til behandling af funktionel tilbagegang
DK3307262T3 (da) Forbindelser til anvendelse ved behandling af neuromuskulære lidelser
EP3756605C0 (en) SKIN TREATMENT DEVICE
DK3481846T3 (da) 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande
DK3185957T3 (da) Patisiran til anvendelse ved behandlingen af transthyretin-medieret amyloidosis
PL3503890T3 (pl) Stosowanie pridopidyny w leczeniu dystonii
DK3551166T3 (da) Topisk phenytoin til anvendelse i behandling af periferisk neuropatisk smerte
DK2994157T3 (da) Tafa4-forbindelser og anvendelser deraf til behandling af smerte
DK3710000T3 (da) Tradipitant til anvendelse til behandling af gastroparese
DK3439663T3 (da) Fremgangsmåder til behandling af pædiatriske cancere
DK3391902T3 (da) Plasminogen til anvendelse i behandlingen af diabetisk angiokardiopati
LT3478719T (lt) Antisklerostinų antikūnų naudojimas gydant osteogenesis imperfecta
DK3374497T3 (da) Modificerede makrofager til anvendelse i behandlingen af kræft
DK3149049T3 (da) Il-22 til anvendelse til behandling af stofskiftesygdomme
DK3532067T3 (da) Liposomal formulering til anvendelse til behandling af cancer
DK3302519T3 (da) Ornithodoros-moubata-komplement-inhibitor til anvendelse i behandlingen af akut graft-versus-host-sygdom
DK3452475T3 (da) Tetrahydropyridodiazepinforbindelser til at behandle smerte og smerterelaterede tilstande
PL3732294T3 (pl) Tymohydrochinon do stosowania w leczeniu hiperglikemii
DK3236960T3 (da) Fluralaner til anvendelse i behandling af demodicose
HUE057257T2 (hu) Folyékony készítmény gyomor- és nyelõcsõ reflux kezelésében történõ alkalmazásra
EP3630331C0 (en) FLUID TREATMENT